Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

HTG Molecular Diagnostics Reports Second Quarter 2017 Results

Posted on: 08 Aug 17

TUCSON, Ariz., Aug. 08, 2017 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a provider of instruments, reagents and services for molecular profiling applications, today reported financial results for the three and six month periods ended June 30, 2017.

Recent Accomplishments & Highlights:

  • Announced the initiation of our second companion diagnostic development project with QIAGEN. Under this partnership, we are developing NGS gene expression profiling assays for multiple cancer therapies.
  • Announced the launch of our research use only HTG EdgeSeq PATH Assay.
  • Announced the expansion of our IVD Agreement with Illumina, Inc. to, among other things, extend the agreement and increase the number of test kits that may be developed for use with Illumina sequencing technology.
  • Achieved revenue of $1.8 million and $3.1 million for the three and six months ended June 30, 2017, respectively.

“The second quarter was very productive for HTG, highlighted by the expansion of our pharma companion diagnostic pipeline. We now have three clinical development programs including two in partnership with QIAGEN, further validating the combined value proposition that our partnership brings to pharma clients,” said TJ Johnson, President and CEO. “We are pleased with our growing momentum and expect full year 2017 revenue in the range of $9.0 million to $12.0 million.”

Second Quarter 2017 Financial Results:

Revenue for the second quarter of 2017 was $1.8 million, driven primarily by biopharmaceutical customer revenue, which accounted for the majority of the $1.4 million of service revenue for the quarter. Consumables revenue was $0.4 million for the quarter.

Net loss from operations for the second quarter of 2017 was $5.5 million, compared to $6.4 million for the second quarter of 2016. Net loss per share was $(0.60) for the second quarter of 2017 compared to $(0.98) for the second quarter of 2016.

HTG ended the second quarter with $13.4 million in total cash and cash equivalents.

Financial Outlook for 2017:

HTG is providing guidance for full year 2017 revenue in the range of $9.0 million to $12.0 million.

Conference Call and Webcast:

HTG will host an investment community conference call today beginning at 4:30 p.m. ET. Individuals interested in listening to the conference call may dial (866) 394-4225 for domestic callers, or (678) 509-7535 for international callers, conference ID 55006903, or access the webcast on the investor relations section of the Company’s website at: The webcast will be available on the Company’s website for 90 days following the completion of the call.

About HTG:

Headquartered in Tucson, Arizona, the mission of HTG is to empower precision medicine at the local level. In 2013, the Company commercialized its first instrument platform and a portfolio of RNA assays that leveraged HTG's original proprietary nuclease protection chemistry. Continuous improvement led to the 2014 launch of the Company’s HTG EdgeSeq product line, which automates sample and targeted library preparation for next-generation sequencing. Additional information is available at

Safe Harbor Statement:

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our partnership with QIAGEN, our strategic priorities and revenue expectations for 2017. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based upon management’s current expectations, are subject to known and unknown risks, and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation, the risk that we may not realize the benefits expected under our collaboration agreements, the risk that we may not achieve our revenue expectations for 2017 (including, without limitation, due to variations from our expectations in the amount or timing of work we perform under one or more companion diagnostic development programs with large pharma customers, which development programs comprise an increasing portion of our business and therefore have the ability to significantly impact the timing and amount of revenue recognized in one or more fiscal periods), risks associated with our ability to successfully commercialize our products; the risk that our products and services may not be adopted by biopharmaceutical companies or other customers as anticipated, or at all; our ability to manufacture our products to meet demand; the level and availability of first party payor reimbursement for our products; our ability to effectively manage our anticipated growth; our ability to protect our intellectual property rights and proprietary technologies; our ability to operate our business without infringing the intellectual property rights and proprietary technology of first parties; competition in our industry; the ability of additional capital and credit availability; our ability to attract and retain qualified personnel; and product liability claims. These and other factors are described in greater detail in our filings with the Securities and Exchange Commission, including without limitation our Quarterly Report on Form 10-Q for the quarter ended March 31, 2017. All forward-looking statements contained in this press release speak only as of the date on which they were made, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

-Financial tables follow-

HTG Molecular Diagnostics, Inc. 
Statements of Operations 
  Three Months Ended June 30,  Six Months Ended June 30, 
  2017  2016  2017  2016 
  Product $407,177  $577,127  $948,321  $1,177,317 
  Service  1,353,579   1,318,689   2,183,604   1,583,731 
Total revenue  1,760,756   1,895,816   3,131,925   2,761,048 
Cost of revenue  1,236,904   932,976   2,532,206   1,776,446 
Gross margin  523,852   962,840   599,719   984,602 
Operating expenses:                
  Selling, general and administrative  4,413,437   4,712,637   8,651,904   9,406,345 
  Research and development  1,618,889   2,611,591   2,885,952   4,605,692 
Total operating expenses  6,032,326   7,324,228   11,537,856   14,012,037 
Operating loss  (5,508,474)  (6,361,388)  (10,938,137)  (13,027,435)
Other expense, net  (332,428)  (489,355)  (718,759)  (846,333)
Net loss before income taxes  (5,840,902)  (6,850,743)  (11,656,896)  (13,873,768)
Provision for income taxes     860   280   4,259 
Net loss $(5,840,902) $(6,851,603) $(11,657,176) $(13,878,027)
Net loss per share, basic and diluted $(0.60) $(0.98) $(1.31) $(2.00)
Shares used in computing net loss per share, basic and diluted  9,769,322   7,018,502   8,875,177   6,952,012 

HTG Molecular Diagnostics, Inc. 
Balance Sheets 
  June 30,  December 31, 
  2017  2016 
Assets (Unaudited)     
Current assets:        
Cash and cash equivalents $13,398,036  $7,507,659 
Short-term investments available-for-sale, at fair value     4,304,901 
Accounts receivable  1,550,868   1,377,441 
Inventory, net  1,313,507   1,511,053 
Prepaid expenses and other  468,431   433,328 
Total current assets  16,730,842   15,134,382 
Deferred offering costs     49,630 
Property and equipment, net  2,880,487   3,270,197 
Total assets $19,611,329  $18,454,209 
Liabilities and stockholders' deficit        
Current liabilities:        
Accounts payable $1,343,912  $761,663 
Accrued liabilities  1,213,611   1,670,286 
Deferred revenue  637,929   335,659 
NuvoGen obligation - current  509,618   604,751 
Term loan payable - current  6,668,789   6,389,782 
Other current liabilities  224,875   258,850 
Total current liabilities  10,598,734   10,020,991 
Term loan payable - non-current, net of discount and debt issuance costs  2,214,820   5,389,137 
NuvoGen obligation - non-current, net of discount  7,811,866   8,017,356 
Other non-current liabilities  533,806   619,587 
Total liabilities  21,159,226   24,047,071 
Commitments and Contingencies        
Total stockholders’ deficit  (1,547,897)  (5,592,862)
Total liabilities and stockholders' deficit $19,611,329  $18,454,209 


Last updated on: 09/08/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.